A Chinese biotechnology company announced Wednesday that it has struck a major licensing deal with Belgian pharmaceutical giant UCB for an experimental treatment targeting autoimmune conditions, with the agreement potentially worth more than $1.1 billion.
Antengene Corporation revealed that UCB will pay $60 million immediately and could provide additional payments exceeding $1.1 billion if specific development goals are achieved for the experimental drug ATG-201.
In a company statement posted online, Antengene highlighted that the partnership demonstrates the “unique” capabilities of its drug development platform. Following the announcement, the company’s Hong Kong stock shares climbed approximately 6% during Wednesday morning trading.
The experimental medication ATG-201 is designed to treat autoimmune conditions related to B-cells. Antengene intends to file for clinical trial approval in both Australia and China during the opening quarter of 2026, and once initial phase I testing concludes, UCB will assume responsibility for continued development.
The licensing arrangement grants UCB global rights to develop, produce, and market ATG-201, along with access to related manufacturing processes. Beyond the initial $60 million payment, Antengene stands to receive additional compensation tied to “certain conditions,” development achievements, and commercial success markers, plus ongoing royalty payments based on future sales revenue.
